Mega Genomics Limited (HK:6667) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mega Genomics Limited reports a robust growth of 8.5% in revenue and a 5.3% increase in net profit for the first half of 2024, compared to the same period in 2023. Despite a significant 93.1% drop in cancer screening services, consumer genetic testing services surged by 83.2%. The company, a leader in China’s genetic testing market, has conducted over 21 million tests since its inception and is expanding its in-house developed product line.
For further insights into HK:6667 stock, check out TipRanks’ Stock Analysis page.